Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

Abstract Introduction Access to first-line immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC) remains limited in many low- and middle-income countries. Consequently, tyrosine kinase inhibitors (TKIs) are still widely used. This study investigates the impact of f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Omer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, Hilal Karakas, Serhat Sekmek, Saadet Sim, Selver Isık, Murat Günaltılı, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Cengiz Karacin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Emre Yekedüz, Yüksel Ürün
Format: Artigo
Idioma:Inglês
Publicat: BMC 2025-07-01
Col·lecció:BMC Cancer
Matèries:
Metastatic renal cell cancer
Pazopanib
Sunitinib
Nivolumab
Accés en línia:https://doi.org/10.1186/s12885-025-14654-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars